Defence Therapeutics Income Statement

Financials in millions CAD. Fiscal year is July - June.

Millions CAD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Selling, General & Admin	2.38	1.52	2.96	2.6	3.14	1.06
Research & Development	0.89	0.8	3.86	3.58	3.76	1.16
Amortization of Goodwill & Intangibles	-	-	0.04	0.01	-	-
Operating Expenses	4.09	3.19	12.75	6.49	7.27	2.83
Operating Income	-4.09	-3.19	-12.75	-6.49	-7.27	-2.83
Interest Expense	-0.3	-0.32	-0.4	-0.26	-	-
Interest & Investment Income	0	0	0.02	0.01	-	-
Currency Exchange Gain (Loss)	0.03	-0.01	0	-0.07	-0.02	-
Other Non Operating Income (Expenses)	-0.06	-0.08	-0.08	-0.05	-0.05	-0.03
EBT Excluding Unusual Items	-4.41	-3.6	-13.19	-6.87	-7.34	-2.86
Other Unusual Items	0.08	0.08	-	-	-	-
Pretax Income	-4.33	-3.52	-13.19	-6.87	-7.34	-2.86
Income Tax Expense	-	-	-	-0.11	-	-
Net Income	-4.33	-3.52	-13.19	-6.76	-7.34	-2.86
Net Income to Common	-4.33	-3.52	-13.19	-6.76	-7.34	-2.86
Shares Outstanding (Basic)	54	50	45	40	36	27
Shares Outstanding (Diluted)	54	50	45	40	36	27
Shares Change (YoY)	19.06%	11.64%	12.54%	9.93%	35.65%	2719.76%
EPS (Basic)	-0.08	-0.07	-0.30	-0.17	-0.20	-0.11
EPS (Diluted)	-0.08	-0.07	-0.30	-0.17	-0.20	-0.11
Free Cash Flow	-4.95	-3.4	-4.49	-7.72	-6.04	-2.29
Free Cash Flow Per Share	-0.09	-0.07	-0.10	-0.20	-0.17	-0.09
EBITDA	-4.06	-3.14	-12.68	-6.48	-	-
D&A For EBITDA	0.03	0.05	0.07	0.01	-	-
EBIT	-4.09	-3.19	-12.75	-6.49	-7.27	-2.83
Advertising Expenses	-	0.53	1.71	1.96	2.52	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.